Article
The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer.
Journal of cancer research and clinical oncology - 1 May 2015
Söderlund Leifler K, Asklid A, Fornander T, Stenmark Askmalm M
Abstract excerpt
PURPOSE: RAD51, a central player in the response to DNA damage, has been suspected to contribute to tumour resistance to therapy. A single-nucleotide polymorphism, RAD51 135G>C, in the untranslated region of the RAD51 gene elevates breast cancer risk among BRCA2 carriers. In this study, it was in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
